The strong efficacy and safety data could attract partnership interest or funding for later-stage trials. Monitor for secondary endpoint completion in January 2027 and any subsequent partnership announcements.
Price Chart
Executive Summary
AIM ImmunoTech announced positive Phase 2 data for Ampligen in recurrent ovarian cancer, showing a 50% objective response rate, 32.5-month median overall survival, and no Grade 4/5 toxicities. The results suggest Ampligen may overcome immunotherapy resistance, but larger trials are needed.
Key Facts
- 50% Objective Response Rate (ORR) including 21% complete responses
- 79% Clinical Benefit Rate
- Median Overall Survival of 32.5 months
- Durable responses exceeding 70+ months in select patients
- No Grade 4 or 5 toxicities observed
- Single-arm Phase 2 trial; final secondary endpoint data expected January 2027
Financial Impact
Pre-revenue company; data supports future partnership/licensing potential but no immediate financial impact
Risk Factors
- Single-arm Phase 2 trial design limits comparative efficacy conclusions
- Requires larger randomized trials for regulatory approval
- Small market cap ($4M) and cash burn risk; may need dilution to fund development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3289988 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 25d ago | DEF 14A | $0.1877 | awaiting T+20 | — | $0.1600 (−14.76%) |
Sep 22, 2026 4w ago | Press Release | $0.2156 $0.1662 | ▼ −22.91% | ▼ −22.35% | $0.1600 (−25.79%) |
Sep 14, 2026 5w ago | 8-K | $0.2100 | awaiting T+20 | — | $0.1600 (+23.81%) |
Aug 11, 2026 10w ago | 8-K | $0.2500 $0.2332 | ▼ −6.72% | ▼ −5.66% | $0.1600 (−36.00%) |
Aug 10, 2026 10w ago | 8-K | $0.2630 | awaiting T+20 | — | $0.1600 (+39.16%) |
Aug 10, 2026 10w ago | Press Release | $0.2630 | awaiting T+20 | — | $0.1600 (+39.16%) |
Aug 5, 2026 11w ago | 8-K | $0.2800 $0.2346 | ▼ −16.21% | ▼ −15.61% | $0.1600 (−42.86%) |
Aug 3, 2026 11w ago | Press Release | $0.2600 $0.2260 | ▼ −13.08% | ▼ −14.31% | $0.1600 (−38.46%) |
Jun 24, 2026 17w ago | EFFECT | $0.3740 $0.2534 | ▲ +32.25% | ▲ +34.18% | $0.1600 (+57.22%) |
Jun 18, 2026 18w ago | S-1 | $0.3799 $0.2730 | ▲ +28.14% | ▲ +28.67% | $0.1600 (+57.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers